Patents Assigned to CHAPERONE THERAPEUTICS, INC.
  • Substituted pyrazoles as heat shock transcription factor activators
    Patent number: 9717709
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 1, 2017
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Substituted pyrazoles as heat shock transcription factor activators
    Patent number: 9718784
    Abstract: The present invention relates to substituted pyrazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof) and pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 1, 2017
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose Serafin Mendoza
  • Substituted 1,3-thiazoles as heat shock transcription factor 1 activators
    Patent number: 9447058
    Abstract: The present invention relates to 1,3-thiazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: September 20, 2016
    Assignees: Duke University, Chaperone Therapeutics, Inc.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Substituted pyrazoles as heat shock transcription factor activators
    Patent number: 9315449
    Abstract: The present invention relates to substituted pyrazole compounds, methods for their discovery, and their research and therapeutic uses, and pharmaceutical Formulations thereof. In particular, the present invention provides substituted pyrazole compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: April 19, 2016
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC
    Inventors: Dennis J Thiele, Daniel W Neef, Jose S Mendoza
  • Substituted 1,3-thiazoles as heat shock transcription factor 1 activators
    Patent number: 9156775
    Abstract: The present invention relates to 1,3-thiazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: October 13, 2015
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
    Publication number: 20130267543
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: November 8, 2011
    Publication date: October 10, 2013
    Applicants: CHAPERONE THERAPEUTICS, INC., DUKE UNIVERSITY
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza